Cipla Limited (CIPLA.NS) NSE

1,374.70

-4.6(-0.33%)

Updated at June 03 10:41AM

Currency In INR

Key Executives

Name	Title	Pay	Year Born
Achin Gupta	MD, Global CEO & Additional Director	0	1976
Rajendra Kumar Chopra	Compliance Officer & Company Secretary	15.3M	N/A
Ashish Adukia	Global Chief Financial Officer	0	N/A
Diksha Maheshwari	Head of Investor Relations	0	N/A
Sneha Hiranandani	Chief Information Officer	0	N/A
Arun Kakatkar	Global Chief People Officer	0	N/A
Dinesh Ramniranjan Jain	Senior Vice President & Head of Corporate Finance	0	N/A
Pradeep Bhadauria	Global Chief Scientific Officer	0	N/A
Heena Kanal	Senior Vice-President of Corporate Communications	0	N/A
Sushrut Kulkarni	President & Global Chief Integrated Product Development and Member of the Management Council	0	1970
Meera Vanjari	Global General Counsel	0	N/A

Name

Title

Pay

Year Born

Achin Gupta

MD, Global CEO & Additional Director

1976

Rajendra Kumar Chopra

Compliance Officer & Company Secretary

15.3M

N/A

Ashish Adukia

Global Chief Financial Officer

N/A

Diksha Maheshwari

Head of Investor Relations

N/A

Sneha Hiranandani

Chief Information Officer

N/A

Arun Kakatkar

Global Chief People Officer

N/A

Dinesh Ramniranjan Jain

Senior Vice President & Head of Corporate Finance

N/A

Pradeep Bhadauria

Global Chief Scientific Officer

N/A

Heena Kanal

Senior Vice-President of Corporate Communications

N/A

Sushrut Kulkarni

President & Global Chief Integrated Product Development and Member of the Management Council

1970

Meera Vanjari

Global General Counsel

N/A

Description

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.